Results 221 to 230 of about 50,613 (304)

Incidence rate and risk factors of arrhythmias in patients with psoriatic arthritis. [PDF]

RMD Open
Almansouri AY, Li J, Bumbulis L, Alhadari A, Colaco K, Harvey P, Akhtari S, Chandran V, Gladman DD, Cook RJ, Eder L.   +10 more
europepmc   +1 more source

Synovial Fluid Biomarkers Reflect Pre‐ and Postoperative Clinical Features in Rotator Cuff Tears, Independent of Tear Size

Journal of Orthopaedic Research, Volume 44, Issue 6, June 2026.
ABSTRACT Synovitis is a major contributor to pain and dysfunction in rotator cuff tears (RCTs), yet it remains unclear whether routine synovial fluid (SF) parameters reflect clinical features independent of tear size, operation method, and patient age.
Seungmin Jeong, Jong Min Lee, Jeong‐Hyun Koh, Doohyung Lee   +3 more
wiley   +1 more source

The Role of Central Sensitization and Emotional Comorbidities in Temporomandibular Involvement Among Patients with Psoriatic Arthritis. [PDF]

Life (Basel)
Blanco JA, Márquez A, Toledano E, Queiro R, Martín-Vallejo J, Fernández-Gómez MJ, Chacón C, Díaz-Peña R, Martín D, Hidalgo C, Sánchez MD, León González M, Montilla C.   +12 more
europepmc   +1 more source

Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 6, Page 1427-1434, June 2026.
Abstract Objectives Adalimumab is commonly used to induce and maintain remission in pediatric Crohn's disease (CD). However, data on the efficacy and safety of high‐dose adalimumab in this population are limited. This study aimed to evaluate the therapeutic effectiveness and safety of weekly high‐dose adalimumab (80 mg) in pediatric CD patients ...
Eyal Cohen‐Sela, Anat Yerushalmy‐Feler, Firas Rinawi, Esther Orlanski‐Meyer, Raouf Nassar, Ramit Magen‐Rimon, Yael Weintraub, Raanan Shamir, Dror S. Shouval, Manar Matar   +9 more
wiley   +1 more source

Development and validation of a new ultrasound score (SONAR-7) for synovitis in psoriatic arthritis and axial spondyloarthritis. [PDF]

RMD Open
Elsehrawy GG, Courvoisier DS, Deman E, Dan D, Micheroli R, Ziswiler H, Zufferey P, Brulhart L, Nissen MJ.   +8 more
europepmc   +1 more source

Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study

JEADV Clinical Practice, Volume 5, Issue 2, Page 495-501, June 2026.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru, Nesrine Brahimi, Haleh Zabihi, Cathryn Sibbald, Kyle Seigel, Delaram Shojaei, Eric McMullen, Afsaneh Alavi, Lily Archaempong, Aaron M. Drucker, Adam Weizman, Kenneth Croitoru, Robert Inman, Vincent Piguet   +13 more
wiley   +1 more source

Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study. [PDF]

Sci Rep
Gentileschi S, Terribili R, Gaggiano C, Fiorentini E, Cometi L, Cigolini C, Perrotta FM, Scriffignano S, Di Cato L, Panaccione A, Niccoli L, Cantini F, Benucci M, Li Gobbi F, Delle Sedie A, Vitale A, Lubrano E, Frediani B, Guiducci S.   +18 more
europepmc   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1206-1209, June 2026.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

JEADV Clinical Practice, Volume 5, Issue 2, Page 517-528, June 2026.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard, Aaron Keal, James Hetherington, Sophie Barlow, David Wu, Melany Worbes‐Cerezo, Alexander Litvintchouk   +6 more
wiley   +1 more source

Metabolic and Inflammatory Disorders-Main Influencers of Psoriatic Arthritis Activity. [PDF]

Curr Health Sci J
Suiu LI, Ciurea PL, Bita CE, Porta F, Vreju FA.   +4 more
europepmc   +1 more source